AlphaFold predicted structure
TRAF3IP2 · O43734
Mean pLDDT
53.2/ 100
Low
574 residues
Confidence breakdown
- Very high(≥ 90)15%
- Confident(70–90)11%
- Low(50–70)12%
- Very low(< 50)62%
Open interactive 3D viewer
AlphaFold (Jumper et al., 2021) · CC BY 4.0
TRAF3IP2
Chr 6q21TRAF3 interacting protein 2
- Aliases:
- DKFZP586G0522, ACT1, CIKS
- MANE:
- ENST00000368761.11
Annotations refreshed 1 month ago.
Predicted protein structure
Clinical relevance (Genomics England PanelApp)
Diagnostic Grade (Green)
COVID-19 research
BIALLELIC, autosomal or pseudoautosomalPrimary immunodeficiency or monogenic inflammatory bowel disease
BIALLELIC, autosomal or pseudoautosomalGeneralised pustular psoriasis
Unknown
Disease associations (Open Targets)
Chronic mucocutaneous candidosis
0.72psoriasis
0.67rheumatoid arthritis
0.59psoriasis vulgaris
0.52psoriatic arthritis
0.52type 2 diabetes mellitus
0.43skin disorder
0.43inflammatory bowel disease
0.41neurodegenerative disease
0.41chronic mucocutaneous candidiasis
0.38
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Protein function (UniProt)
E3 ubiquitin ligase TRAF3IP2
E3 ubiquitin ligase that catalyzes 'Lys-63'-linked polyubiquitination of target protein, enhancing protein-protein interaction and cell signaling (PubMed:19825828). Transfers ubiquitin from E2 ubiquitin-conjugating enzyme UBE2V1-UBE2N to substrate protein (PubMed:19825828). Essential adapter molecule in IL17A-mediated signaling (PubMed:19825828, PubMed:24120361). Upon IL17A stimulation, interacts with IL17RA and IL17RC receptor chains through SEFIR domains and catalyzes 'Lys-63'-linked polyubiquitination of TRAF6, leading to TRAF6-mediated activation of NF-kappa-B and MAPkinase pathways (PubMed:19825828)
Diseases associated with TRAF3IP2
Curated MONDO disease pages that list TRAF3IP2 among their top associated genes.